Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 3Other solid neoplasm 2Gynecologic 2Breast 1

Conditions

Breast Neoplasms 27Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Carcinoma, Non-Small-Cell Lung 13Melanoma 10Neoplasm Metastasis 9Colorectal Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Urogenital Neoplasms 4Multiple Myeloma 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Prostatic Neoplasms 2Osteosarcoma 2Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 9Gemcitabine 5Cisplatin 5Nivolumab 3Drug Therapy 3budigalimab 2Paclitaxel 2Injections 2Docetaxel 2Carboplatin 2zenocutuzumab 1venetoclax 1tislelizumab 1spartalizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1nilotinib 1margetuximab 1lenvatinib 1futibatinib 1fludarabine 1entrectinib 1durvalumab 1crenigacestat 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × fludarabine × Breast × Clear all
NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡